Date published: 2026-5-9

1-800-457-3801

SCBT Portrait Logo
Seach Input

Trilostane (CAS 13647-35-3)

5.0(1)
Write a reviewAsk a question

See product citations (2)

Application:
Trilostane is A 3β-hydroxysteroid dehydrogenase inhibitor
CAS Number:
13647-35-3
Purity:
≥99%
Molecular Weight:
329.43
Molecular Formula:
C20H27NO3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Trilostane is an inhibitor of isoforms 3β-HSD and 3β-HSD2 of the enzyme 3β-hydroxysteroid dehydrogenase, which plays a role in adrenal steroid biosynthesis. Investigators believe that Arg195 in 3β-HSD versus Pro195 in 3β-HSD2 attributes to the competitive inhibition of 3β-HSD, but not 3β-HSD2 by Trilostane. Research shows that trilostane is effective in suppressing the intracellular production of androstenedione, testosterone, and dihydrotestosterone in LNCaP-FGC prostate cancer cells and inhibiting cortisol biosynthesis in the human adrenal gland. This product serves as a useful tool in steroid biosynthesis research.


Trilostane (CAS 13647-35-3) References

  1. Differentiation-dependent progesterone synthesis and metabolism in NT2-N human neurons.  |  Pistritto, G., et al. 2009. Exp Neurol. 217: 302-11. PMID: 19306873
  2. 3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer.  |  Evaul, K., et al. 2010. Endocrinology. 151: 3514-20. PMID: 20534728
  3. Selective inhibition of human 3β-hydroxysteroid dehydrogenase type 1 as a potential treatment for breast cancer.  |  Thomas, JL., et al. 2011. J Steroid Biochem Mol Biol. 125: 57-65. PMID: 20736065
  4. Trilostane, an inhibitor of 3β-hydroxysteroid dehydrogenase, has an agonistic activity on androgen receptor in human prostate cancer cells.  |  Takizawa, I., et al. 2010. Cancer Lett. 297: 226-30. PMID: 20831980
  5. Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis.  |  Komanicky, P., et al. 1978. J Clin Endocrinol Metab. 47: 1042-51. PMID: 233687
  6. Possible therapeutic effect of trilostane in rodent models of inflammation and nociception.  |  Tung, D., et al. 2013. Curr Ther Res Clin Exp. 75: 71-6. PMID: 24465047
  7. Long-term survival of dogs with adrenal-dependent hyperadrenocorticism: a comparison between mitotane and twice daily trilostane treatment.  |  Arenas, C., et al. 2014. J Vet Intern Med. 28: 473-80. PMID: 24495125
  8. Expression of 11β-hydroxysteroid dehydrogenase isoforms in canine adrenal glands treated with trilostane.  |  Teshima, T., et al. 2014. Vet J. 200: 452-5. PMID: 24745768
  9. Comparison of adrenocorticotropic hormone stimulation test results started 2 versus 4 hours after trilostane administration in dogs with naturally occurring hyperadrenocorticism.  |  Bonadio, CM., et al. 2014. J Vet Intern Med. 28: 1239-43. PMID: 24863172
  10. Prognostic factors for survival in dogs with pituitary-dependent hypercortisolism treated with trilostane.  |  Fracassi, F., et al. 2015. Vet Rec. 176: 49. PMID: 25170036
  11. Cortisol Concentrations in Well-Regulated Dogs with Hyperadrenocorticism Treated with Trilostane.  |  Midence, JN., et al. 2015. J Vet Intern Med. 29: 1529-33. PMID: 26374943
  12. Multicenter study of trilostane: a new hormonal agent in advanced postmenopausal breast cancer.  |  Williams, CJ., et al. 1987. Cancer Treat Rep. 71: 1197-201. PMID: 3690530
  13. Studies on the metabolism of trilostane, an inhibitor of adrenal steroidogenesis.  |  Mori, Y., et al. 1981. Chem Pharm Bull (Tokyo). 29: 2646-52. PMID: 7349283

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Trilostane, 10 mg

sc-208469
10 mg
$228.00

Trilostane, 100 mg

sc-208469A
100 mg
$1217.00